OXB provides an update to coincide with its Annual General Meeting being held at 3pm BST at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025o date, as it continues to provide viral vector manufacturing services to a diversified portfolio of clients. The Company remains on track to deliver the outlook set out in the Preliminary Results for the year ended 31 December 2024, published on 9 April 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford Biomedica Reports Strong Momentum and Reaffirms Financial Guidance
- Oxford BioMedica Announces Change in Voting Rights
- Oxford Biomedica Seeks Block Listing on London Stock Exchange
- OXB highlights launch of Innovation, Technolgoy Excellence Board
- Oxford Biomedica Launches Innovation and Technology Excellence Board